-
Retatrutide: What Emerging Research Suggests About This Promising Investigational Peptide
Retatrutide, a triple-hormone receptor agonist still in clinical trials, is generating excitement for its potential to support significant weight loss and metabolic health improvements.
-
FDA Advisory Committee Gives Favorable Nod to Six Peptides, Signaling Progress Toward Broader Access
An FDA advisory committee has voted in favor of six peptides, marking an encouraging step in the ongoing regulatory process that could shape their future availability. The decision reflects growing scientific engagement with peptide therapies.
-
FDA Advisory Panel Signals Support for Wider Access to BPC-157 and TB-500
A majority of FDA advisers have voiced support for making peptides like BPC-157 and TB-500 available in the U.S., marking a potentially significant step toward expanded legal access.
-
Eli Lilly’s Oral Weight-Loss Medication Receives FDA Approval
The FDA has approved Eli Lilly’s new weight-loss pill, offering patients an oral alternative to injectable GLP-1 therapies for weight management.
-
Kither Biotech Announces Successful Completion of Phase 1 Clinical Trial for Novel Peptide Therapy
Kither Biotech has successfully completed a Phase 1 clinical trial for its peptide-based therapeutic candidate, marking a key milestone in the company’s mission to develop new treatments for respiratory disease.
-
FDA Signals Potential Support for Peptide Therapeutics Under New Leadership
Reports suggest the FDA under new leadership may take a more favorable stance toward peptide-based treatments, potentially opening doors for expanded research and development in this growing therapeutic category.
-
Lilly’s Triple-Acting Obesity Peptide Meets Key Goal in Phase 3 Trial
Eli Lilly announced its investigational triple-hormone-receptor obesity drug achieved its primary goal in a Phase 3 study, marking another step forward for next-generation weight management therapies.
-
Understanding Peptides: How GLP-1s and Insulin Are Helping Patients Today
A new patient-education overview from NewYork-Presbyterian explains how peptide-based therapies like GLP-1 medications and insulin are already improving health outcomes for millions.
-
Expanding Access: New Online Education Programs Help Medical Providers Master Peptide Therapies
New online training programs are helping medical providers build a deeper, more structured understanding of peptide therapies, supporting safer and more informed clinical use.
-
FDA Advisory Panel Gives Green Light to Six Peptides for Compounding Use
An FDA advisory panel has voted to support the inclusion of six peptides on a list used by compounding pharmacies, a step that could expand patient access to these therapies.